Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Approvals Jump 44%; FDA Works On Roadblocks As Review Times Drop

Executive Summary

FDA's Office of Generic Drugs approved 380 abbreviated new drug applications in 2004, a 44% increase over the previous year

You may also be interested in...



FDA Re-Examining Citizen Petition Process To Speed Generic Approvals

FDA is taking another look at its citizen petition review process in an attempt to expedite decisions on generic drug applications, Center for Drug Evaluation & Research Acting Director Steven Galson told the Generic Pharmaceutical Association's annual meeting Feb. 25 in Boca Raton, Fla

ANDA Reviews Reorganized To Speed Approval; Dissolution Now First In Line

The Division of Bioequivalence in FDA's Office of Generic Drugs has begun conducting dissolution tests earlier in the ANDA review process to speed approvals

Drug Substance Guidance Rewrite Sparks CMC/GMP Boundary Debate

The redrafting process on FDA's drug substance guidance is fanning debate over the role of the marketing application in the evolution of a more science- and risk-based quality regulatory paradigm

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel